Multiple Sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in the country. Two approved disease-modifying therapies (DMTs)—IFN-β-1b (Bayer’s Betaferon) and teriflunomide (Sanofi’s Aubagio)—and immunosuppressants such as methotrexate, mitoxantrone, rituximab, azathioprine are used to treat MS in China. The late-phase MS pipeline in China includes two S1PR modulators(siponimod [Novartis’s Mayzent] and the recently approved fingolimod [Novartis’s Gilenya]) and an anti-CD52 MAb(alemtuzumab [Sanofi’s Lemtrada]). Siponimod is under regulatory review by the NMPA, while alemtuzumab is eligible for priority review. The NMPA is focused on granting fast-track designations to therapies that address urgent clinical need in China, thus allowing such agents to move directly to the market filing stage based on foreign clinical trial data. Therefore, current MS agents in China are likely to witness stiff competition in the next few years because of the expected launch of new therapies.
- How large is China’s drug-treatable MS population, and how will drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s MS market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the MS pipeline in China? What sales/uptake could they secure in MS? What are interviewed experts’ opinions on the key emerging therapies?
- What are the key drivers and constraints in the Chinese MS market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology and keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by five country-specific interviews with thought-leading neurologists, supported by survey data collected for this and other DRG research.
Diagnosed prevalence of MS by disease subtype. Clinically relevant and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key MS therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 2 drugs; coverage of select early-phase products.
- Multiple Sclerosis - Geographic Focus: China - Multiple Sclerosis | China In-Depth | China
- ChinaIn-Depth - Multiple Sclerosis
Author(s): Karan Verma, MSc; Sunali D. Goonesekera, SM; Akash Saini, Ph.D.
Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.
Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.
Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.
Akash is a Principal Analyst in the China In-Depth team at Decision Resources Group. Since 2016, he has specialized in a range of indications including rare disease indications such as DMD, ALS, ITP, IPF, JIA, and retinitis pigmentosa. He has authored Disease Landscape & Forecast reports, Access & Reimbursement reports, and Treatment Algorithm reports based on primary market research and real-world evidence. Prior to joining DRG, Akash was a post-doctoral fellow at the University of Massachusetts Medical School. He has a Ph.D. from the International Centre for Genetic Engineering and Biotechnology, New Delhi.